In conjunction with the healthcare authorities, a group of practitioners from the FILNEMUS neuromuscular healthcare network has drawn up recommendations for the rational use of intravenous immunoglobulins (IVIg) in chronic inflammatory demyelinating polyneuropathy (CIDP):
- these recommendations arise in the context of the shortage of IVIg experienced by patients with CIDP, particularly at the time of the Covid-19 pandemic,
- they apply to both the public and private sectors,
- the indications and doses are detailed, both for the induction of treatment and for background treatment,
- The question of the differential diagnosis of PCID is also addressed.
In the absence of clear marketing authorisations (MA) for IVIg for dysimmune neuromuscular diseases, specialists will certainly benefit from these recommendations in order to use them.
